

July 3, 2023

The Honorable Anna Eshoo
U.S. House of Representatives
703 Hart Senate Office Building
Washington, D.C. 20510

Dear Congresswoman Eshoo,

I am writing to offer Vizient's support for the Drug Origin Transparency Act. Drug shortages continue to be an enduring challenge for the U.S. healthcare system. Your legislation would take important steps to enhance transparency in the prescription drug marketplace and provide necessary information to allow supply chain stakeholders to act before drug shortages negatively impact the U.S. health system.

Vizient is the nation's leading healthcare performance improvement company. Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality, and market performance for more than 60% of the nation's acute care providers, which includes 97% of the nation's academic medical centers and more than 25% of ambulatory providers. Vizient provides expertise, analytics, and advisory services, as well as a contract portfolio that represents more than \$130 billion in annual purchasing volume, to improve patient outcomes and lower costs. Headquartered in Irving, Texas, Vizient has offices across the United States.

The Drug Origin Transparency Act would provide added clarity to the manufacturing and distribution of active pharmaceutical ingredients (API) and other key components of prescription drugs. Under this legislation, prescription drug manufacturers will be required to regularly report manufacturing details to the FDA, including specific production locations and the origins of API and other critical components, and must also provide this information on the drug's label. These enhancements will help mitigate drug shortages by allowing for proactive identification of potential disruptions, giving supply chain stakeholders an opportunity to find alternative production locations or supplier options.

Vizient recognizes and the severity of ongoing drug shortages and continues to work diligently with suppliers and providers on myriad solutions to mitigate supply disruptions. We are pleased to support this important legislation that will provide much-needed clarity to our drug supply chain and contribute to a more resilient healthcare system.

Thank you for your ongoing leadership on this issue. Please do not hesitate to contact me at shoshana.krillow@vizientinc.com or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krillow
Senior Vice President, Public Policy & Government Relations